Elisabetta Signoriello, Alessio Signori, Giacomo Lus, Giuseppe Romano, Girolama Alessandra Marfia, Doriana Landi, Francesca Napoli, Emanuele D' Amico, Aurora Zanghí, Paola Sofia Di Filippo, Daniele Caliendo, Antonio Carotenuto, Antonio Luca Spiezia, Roberta Fantozzi, Diego Centonze, Matteo Lucchini, Massimiliano Mirabella, Eleonora Cocco, Jessica Frau, Giorgia Teresa Maniscalco, Maria Elena Di Battista, Matteo Foschi, Andrea Surcinelli, Simona Bonavita, Gianmarco Abbadessa, Livia Pasquali, Maria Di Gregorio, Maria Teresa Ferrò, Maria Pia Sormani, Irene Schiavetti
BACKGROUND: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatment-naïve HAMS patients receiving NAT or OCR over three years...
April 6, 2024: Multiple Sclerosis and related Disorders